Author: admin

ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years. ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metas

TORONTO, Nov. 7, 2023 /PRNewswire/ – Representatives from BMO Capital Markets, CIBC, TD Securities, Virtu Financial Inc., and Clearpool Group, joined Rizwan Awan, President, Equity Trading and Head of TMX Markets, Products & Services, TMX Group, to open the market and celebrate the launch

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: